Fundamental analysis by BourseMag|مجله بورس about Stock دسبحا on 5/26/2025

#Assembly #Beaurant 📌 According to the report of the conscious voice; The annual general meeting of Sobhan Pharmaceutical Group is being held with a 5.5 % participation of shareholders The most important points in this session are as follows: Sobhan Drug Company in the first six months of the year, operational revenue, operating profit 2 and net profit of 2 billion tomans. The measures include the production of more than three billion products, the production of nerve and mental drugs, and so on. We got 5 % of the Biosan Food Company, a startup, but successful company and produced the Gardasil vaccine. Overall, the main and sub -companies have offered 5 new products. The development plan included obtaining GMP certification and solids production line projects and central warehouse projects from the company's actions. ✅Darat did not grow much due to the harsh medicine and products. But in Iran Daroo, it was definitely a growing year. Future programs include entering the market for new pharmaceutical products, focusing on the implementation of development projects, and planning for raw material storage. A plan has been planned to reduce facilities in subsidiaries, and this reduction has been applied to KBC and Sobhan Oncology. اری At Sobhan Oncology Company, the replacement of the products is on the agenda and the marketing program has been modified and announced soon. If the marketing is not corrected, it faced a product depot and loss. The company's stock trend is positive and we are confident that recent declines have been offset. The average receipt of the claims in the industry has been an average of 5 days. Industry Broadcasting Company failed to settle the sums in a timely manner, which has caused problems for the company. Some of the claims were paid through the follow -up and the other part of the capital increase was paid. A 2 -meter -long Maleki on Wazra Street is owned by the company, which is of high value and is estimated at the value of KBC. This is effective in profitability and the total value of the company's assets. By changing the fiscal year of some subsidiaries, we are working to minimize the delay in exposing financial statements. In recent years, the pharmaceutical industry has been seriously damaged due to exchange rate fluctuations and delays in government claims. Prices were not appropriate either, and Sobhan Daru Company was no exception. Recent sales reports show that holding measures are effective and we hope that reducing facilities and improving marketing program will significantly improve the company's situation. The dividend was approved per share of 3 Rials.